Influencing the Future of Liver Disease Outcomes
Through Innovative Ascites Fluid Management.
*Fluens in Latin means ‘flowing’
The problem
A Hidden Burden in
Chronic Liver Disease
2.5 MILLION
Cirrhosis Patients by 2030 in the US 1
> 1 MILLION
Decempensated Cirrhosis 2
Ascites is the most common decompensation event3
40%
Develop Hepatorenal Syndrome 4
80% Mortality within 3 months 5
4Lenz, Kurt, et al. “Treatment and management of ascites and hepatorenal syndrome: an update.” Therapeutic advances in gastroenterology 8.2 (2015): 83-100.
4Flamm, Steven L., et al. “The current management of hepatorenal syndrome–acute kidney injury in the United States and the potential of terlipressin.” Liver Transplantation 27.8 (2021): 1191-1202.
Our Solution
Fluens Medical is developing an implantable device that, unlike existing treatments, continuously and safely preserves ascitic fluid within the body, reducing hospital visits due to paracentesis and improving long-term outcomes as a bridge to liver transplant.
The Technology
Fluens’s proprietary technology is a minimally invasive implant designed to continuously manage ascitic fluid by redirecting it back to its source, the vasculature. This bio-inspired approach leverages the body’s natural pathways to restore fluid balance safely and effectively.
Our partners
Fluens Medical 